Particle Peptides

"GLP-3" is Particle's pseudonym for Retatrutide

Particle lists Retatrutide on the catalog as "GLP-3". The product page does not link the two names — buyers searching for "retatrutide" miss it unless they happen to know the alias. The chemical identity is the same (LY3437943, the Eli Lilly triple-agonist GLP-1 / GIP / glucagon receptor candidate). Our pricing index now matches both terms automatically; the GLP-3 SKU shows up at 10mg / €113.81 / ~$121.78 — competitive against Swiss Chems' retatrutide listings on per-mg.

We're flagging the alias as a transparency issue. There's no obvious regulatory reason to relabel it; the more likely driver is generic-search ranking or platform-policy avoidance. Either way, undisclosed name swaps on a still-Phase-3 compound aren't a great signal for naïve buyers.

What the catalog-COA mirror shows

Particle publishes per-batch COAs directly on product pages and we mirror them. The patterns the mirror surfaces:

• 2024-vintage Apigenex-tested batches show a content gap. Multiple SKUs from the 2024 cohort came back in the 70–80% range on label-stated content. The lab — Apigenex (Czech Republic) — assays by HPLC-UV against an external standard, and the methodology choice matters here: HPLC-UV with no MS confirmation is more vulnerable to underfill being misread as low purity, but the directional signal (measured content < label) is the audit-relevant fact regardless of whether it's purity or fill volume that's off.
• 2025+ Liquilabs assays close the gap. Newer batches tested by Liquilabs s.r.o. (Czechia) come back at or above label content. The improvement is real; Particle clearly noticed and switched lab partners. The audit-relevant question for 2026+ buyers is whether the SKU they're receiving is from the new cohort or stale 2024 inventory — this is visible in the batch-ID date prefixes on the COAs we mirror.
• 2026+ batches carry an independent verification URL. Particle's newer COAs embed a Liquilabs public-report link (base.liquilabs.cz/@@public_report?ar_uid=…) as a PDF annotation. 9 of the 72 batches in our mirror have one. Buyers can paste the ar_uid into our COA verifier to cross-check the result against Liquilabs' own server — same trust mechanism as the public.janoshik.com lookup for Janoshik-tested vendors.
• GHK-Cu batch 2025240 — disclosed +40% overfill. A 50mg vial assayed at ~70mg measured content. The batch COA discloses this on the vendor's product page (we mirror it). That's the right way to handle fill variance — disclose it and let buyers calibrate dosing — and it's the rare case in our audit cohort.
• GHRP-6 batch 2023149 — -21% underfill. A 5mg vial assayed at ~3.95mg. Pre-2024 inventory. Worth flagging because GHRP-6 is dosed by mass and a 21% underfill silently shifts the dosing math.

What we ordered (April 2026 cycle smoke test)

The April cycle covered Particle's three highest-volume SKUs: BPC-157 (5 mg), TB-500 (5 mg), and GHK-Cu (50 mg). All three placed in a single order under one alias for shipping benchmarking. Order placed April 4, dispatched April 5, delivered April 8 — four days total. Customer service was tested with a realistic shipping question; response came at the 27-hour mark.

Pricing notes

Particle's pricing is materially below the market average for the compounds we walk daily. The pricing pipeline picks up six tracked-compound matches across categories: BPC-157, TB-500, GHK-Cu, MOTS-c, AOD-9604, and the GLP-3 (Retatrutide) listing. EUR is converted to USD at a fixed ~1.07 mid-2026 rate (overridable via env) for cross-vendor comparison. Bulk tiers stack with the PARTICLE10 coupon.

Verdict

Strong catalog-COA surface, clear methodology improvement curve, and competitive pricing — including one of only two retatrutide carriers in our active cohort. The 2024-vintage content gap is real but largely historical; the GLP-3-to-Retatrutide alias is the live transparency issue. For cost-sensitive buyers comfortable with crypto checkout and willing to verify the batch-date prefix on COAs, Particle is a defensible pick.

Legal entity

OpenGraph metadata on particlepeptides.com lists the operator as PARTICLE, s. r. o. (a Czech/Slovak limited-liability company). Identified via <meta property="og:site_name"> on the homepage — this is the operator's own self-disclosure in their social-card metadata, not external attribution. The disclosure is consistent with the EU-based shipping and EUR-only pricing on the catalog.

FAQ

Is Particle Peptides US or international? EU-based with international shipping to the US among other regions. Transit times to US average longer than domestic-US vendors (5-9 days typical) but pricing is often lower per mg.

Does Particle publish lab tests? Yes. Particle publishes per-batch certificates and historically uses Janoshik Analytical for third-party verification. Test IDs verify at our COA verifier.

What compounds does Particle specialize in? The GLP-1 mainstream (retatrutide, tirzepatide, semaglutide) plus the healing-peptide flagships (BPC-157, TB-500).

How does Particle compare to US vendors on pricing? Often 10-25% cheaper per mg on the GLP-1 mainstream. Trade-off is longer shipping and customs risk for some destinations. See cross-vendor peptides index for current numbers.

Related

• Where to buy retatrutide in 2026
• Shared COA URLs and upstream supply
• How to verify a Janoshik COA

• Janoshik public-tests database↗ — Janoshik Analytical
• Why peptide vendors run alias clusters — vialaudit
• Janoshik 7,164-tests purity analysis — vialaudit